Guide

Neuroactive peptides

Built from index records dated 2026-10-09 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk How this site works

Neuroactive peptides is a group of 4 entries in this index, of which this site describes 2 and holds 2 back pending review.

Only the described entries are counted anywhere on this page.

What this group is

This group holds 4 entries.

No entry in this group carries a receptor or a pathway in its records. The group is held together by the research subject its literature shares, not by a mechanism, and this site does not invent one for it.

The entries described here

Selank

12 records kept: 10 in rodents, 2 not stated. The records kept here are animal and laboratory studies only.
Noopept

12 records kept: 8 in rodents, 4 not stated. The records kept here are animal and laboratory studies only.

Publication years of all 24 records kept for the described entries in this group. Oldest 2017, newest 2025. An old record is not a worse record, but a group whose marks all sit to the left has not been looked at recently.

What is held back

2 entries in this group are built and then held back, because publishing them without a qualified reviewer would risk being read as medical guidance. They are: Semax and Cerebrolysin. This page says nothing about what their records contain. Why entries are held back.

What is not known

Whether the members of this group have anything in common beyond what the counts above show. A shared receptor is a shared target, not a shared result.
What any of these entries does in a body. Nothing on this site has been read in full, and no record here has been appraised by anyone qualified to appraise it.
Anything at all about the held-back entries named above, beyond the fact that they exist and are being withheld.

Where this comes from

This page reprints no wording from the underlying index. These are the published records that index cites for the existence of this group, listed so the grouping can be checked rather than taken on trust.

Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain research (2006). pmid:16996037
Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and peptide letters (2018). pmid:30255741
Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals. CNS & neurological disorders drug targets (2012). pmid:22229324
Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neuroscience letters (2001). pmid:11457573
Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cellular and molecular neurobiology (2010). pmid:19633950
The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of experimental biology and medicine (2001). pmid:11550013
GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in pharmacology (2017). pmid:28293190
The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs of today (Barcelona, Spain : 1998) (2012). pmid:22514792